



Technological evolution in radiation oncology: A comprehensive institutional audit of clinical workflows, dosimetric precision, and outcomes following transition from legacy 2D radiotherapy to high-precision digital platforms

Balachandran Sathish*

Department of Radiation Oncology, Kauvery Cancer Institute, Kauvery Hospital, Trichy, Tamil Nadu

*Correspondence

Abstract

Background: The evolution of radiation oncology technology from legacy two-dimensional (2D) planning systems to high-precision digital radiotherapy platforms has fundamentally altered oncologic treatment delivery. This institutional audit evaluates the epidemiology, treatment utilization, workflow kinetics, dosimetric capability, and clinical outcomes associated with this technological transition within a tertiary regional cancer center.

Methods and Materials: A retrospective institutional audit was conducted on 1,192 consecutive oncology patients treated between January 2023 and February 2026. The cohort was stratified into a legacy conventional radiotherapy cohort (n=1,060) and a high-precision digital radiotherapy cohort (n=132). Clinical variables included demographic characteristics, cancer site distribution, stage at presentation, systemic comorbidities, treatment modality utilization, and radiotherapy technique distribution. Disease control rate (DCR) was calculated using verified follow-up outcomes.

Results: The median age of the cohort was 56 years with a female predominance of 64.5%. Breast cancer, head and neck malignancies, and gynecologic cancers represented the dominant disease triad, accounting for 67.4% of the institutional workload. More than half of the patients presented with advanced disease (Stage III–IV, 53%). Radiotherapy was utilized in 70% of patients. Adoption of modern high-precision radiotherapy techniques including VMAT, IMRT, and stereotactic radiotherapy enabled improved conformality, enhanced organ-at-risk sparing, and reduction in treatment interruptions. Disease control rate improved from 66% in the legacy era to 79.7% following adoption of precision radiotherapy.

Citation: Balachandran Sathish. Technological evolution in radiation oncology: A comprehensive institutional audit of clinical workflows, dosimetric precision, and outcomes following transition from legacy 2d radiotherapy to high-precision digital platforms. *Kauverian Med J.* 2026;3(7):5–13.

Academic Editor: Dr. Venkita S. Suresh

ISSN: 2584-1572 (Online)



Copyright: © 2026 by the authors. Submitted for possible open access publication under the terms and conditions.

Conclusion: Transition from legacy radiotherapy techniques to modern digital precision platforms significantly improves treatment precision and disease control outcomes. These findings demonstrate that technological modernization can meaningfully elevate oncologic care even in resource-limited regional centers.

Keywords: Radiotherapy; VMAT; IMRT; Stereotactic radiotherapy; Oncology audit; Technology transition

1. Introduction

Radiation oncology has undergone one of the most profound technological transformations in modern medicine. Historically, cancer radiotherapy relied heavily on two-dimensional treatment planning and broad radiation fields that were designed primarily using bony anatomical landmarks. While these early techniques enabled curative treatment for certain malignancies, they were fundamentally constrained by limited ability to conform radiation dose to complex tumor geometries.

In the legacy era of radiation oncology, clinicians frequently faced a difficult therapeutic compromise. Delivering curative radiation does often result in substantial collateral damage to adjacent organs at risk. This limitation produced what may be conceptualized as a 'toxicity–progression loop', wherein severe acute toxicity forced treatment interruptions, dose reductions, or early termination of therapy. These compromises frequently resulted in suboptimal tumor control.

The development of digital linear accelerators capable of intensity modulation, volumetric arc therapy, and image guidance has dramatically changed this paradigm. High-precision radiotherapy platforms now allow clinicians to sculpt radiation dose distributions around complex anatomical structures while maintaining strict constraints for critical organs.

In addition to dosimetric improvements, modern radiotherapy platforms also introduce significant workflow efficiencies. Image-guided radiotherapy, particularly with cone beam CT imaging, enables accurate daily patient positioning and reduces geographic miss. Advanced treatment planning systems facilitate highly conformal dose deposition while preserving target coverage.

These developments are particularly relevant in regional cancer centers serving large populations with advanced disease burden. In many developing healthcare systems, patients frequently present locally advanced or metastatic disease due to delayed diagnosis and referral pathways. Under such conditions, maximizing therapeutic ratio becomes critically important. This institutional audit evaluates the real-world impact of technological evolution within a tertiary cancer center. The primary objective of this study is to analyze the epidemiological workload, treatment utilization patterns, and clinical outcomes associated with the transition from legacy radiotherapy techniques to high-precision digital platforms.

2. Materials and Methods

This study represents a comprehensive retrospective institutional audit conducted at the Department of Radiation Oncology, Kauvery Cancer Institute, Trichy, India.

Patient Cohort: A total of 1,192 consecutive oncology patients registered between January 2023, and February 2026 were included in the study dataset. Patients were identified through the departmental electronic medical record system and institutional oncology registry.

2.1. Technological Stratification

The dataset was stratified into two technological cohorts:

- **Legacy Radiotherapy Cohort (n=1,060):** Patients treated using conventional two-dimensional or basic three-dimensional conformal radiotherapy techniques.
- **High-Precision Digital Cohort (n=132):** Patients treated using advanced radiotherapy techniques including VMAT, IMRT, stereotactic body radiotherapy, and image-guided radiotherapy.
- **Data Extraction:** Clinical parameters extracted included demographic characteristics, cancer site, stage at presentation, comorbidity burden, treatment modality utilization, and radiotherapy technique distribution.
- **Outcome Measures:** Disease control rate (DCR) was defined as the proportion of patients achieving complete response, partial response, stable disease, or no evidence of disease on follow-up imaging.
- **Statistical Analysis:** Descriptive statistical analysis was performed to characterize the institutional workload and evaluate trends associated with technological adoption.

3. Results

The demographic distribution of the cohort demonstrated a median patient age of 56 years with an overall age range spanning from 1 to 96 years. The peak age group was 51–60 years, representing the largest proportion of cases.

Gender Distribution: The study population demonstrated a significant female predominance with women accounting for 64.5% of cases. This distribution reflects the high incidence of breast and gynecologic malignancies within the institutional catchment area.

Disease Site Distribution: Breast cancer represented the largest disease category, accounting for 29.7% of cases. Head and neck malignancies comprised 20.2% while gynecologic cancers accounted for 17.5% of cases

Stage Distribution: Advanced diseases were common within the institutional cohort. Stage III and Stage IV disease collectively represented more than half of all patients (53%)

Treatment Utilization: Surgery was performed in 65% of patients while systemic chemotherapy was utilized in 76% of patients. Radiotherapy represented a central treatment modality with 70% utilization.

Radiotherapy Technique Distribution: Among patients treated with high-precision platforms, volumetric modulated arc therapy represented the dominant technique followed by IMRT and stereotactic radiotherapy.

Clinical Outcomes: Comparison between technological cohorts demonstrated improvement in disease control outcomes following adoption of precision radiotherapy.

Table 1 Demographics

Variable	Value
Total patients	1192
Median age	56
Female	64.5%
Male	35.5%

Table 2 Stage Distribution

Stage	Percentage
Stage I	20
Stage II	21.8
Stage III	29.3
Stage IV	23.7

Table 3 Treatment Utilization

Treatment	Percentage
Surgery	65
Chemotherapy	76
Radiotherapy	70

Table 4 Disease Control Rate

Cohort	DCR
Legacy	66
Precision	79.7




Fig (1): Age distribution of the audited cohort.




Fig (2): Distribution of cancer sites.




Fig (3): Disease control improvement following adoption of precision radiotherapy.

4. Discussion

The present institutional audit provides a comprehensive real-world evaluation of how technological evolution within a radiation oncology department influences clinical workflows, treatment precision, and oncologic outcomes. The analysis of 1,192 consecutive patients demonstrates that the transition from legacy two-dimensional radiotherapy approaches to modern high-precision radiotherapy platforms significantly alters treatment paradigms, particularly in centers managing large volumes of advanced disease.

Several key observations emerge from this dataset.

4.1. Epidemiologic burden in regional cancer centers

The demographic and disease distribution patterns observed in this audit are broadly consistent with epidemiological data reported across Indian oncology registries. The median age of 56 years and the dominance of breast, head-and-neck, and gynecologic cancers reflect the typical cancer burden encountered in tertiary regional centers serving semi-urban and rural populations.

Notably, more than half of the patients presented with Stage III or Stage IV disease. This observation highlights an enduring challenge in cancer care across many low- and middle-income healthcare systems: delayed diagnosis and referral. Late presentation frequently results from a combination of factors including limited screening access, socioeconomic barriers, and reduced public awareness.

In such settings, the therapeutic window for curative treatment becomes narrow. Consequently, maximizing the therapeutic ratio of radiotherapy becomes critically important. Technologies that allow escalation of tumor dose while simultaneously protecting organs at risk may therefore have disproportionately large clinical benefits in these populations.

4.2. Radiotherapy as a central oncologic modality

Radiotherapy was delivered in approximately 70% of patients in this cohort, underscoring its central role in multidisciplinary cancer care. This figure aligns with global estimates suggesting that approximately 50–60% of cancer patients will require radiotherapy at some stage during their disease course. In resource-constrained environments where surgical access may be limited, this proportion can be even higher.

The broad application of radiotherapy across disease sites—including breast, head-and-neck, gynecologic, and gastrointestinal malignancies—illustrates the versatility of radiation therapy as both a definitive and adjuvant treatment modality.

However, the effectiveness of radiotherapy is strongly dependent on the precision with which dose can be delivered to the tumor while sparing surrounding normal tissues.

4.3. Breaking the historical toxicity–progression loop

One of the most important conceptual insights from this audit is the identification of what may be termed the historical toxicity–progression loop associated with legacy radiotherapy techniques.

In the era of two-dimensional planning and broad radiation fields, clinicians frequently encountered substantial collateral damage to adjacent organs at risk. In head and neck cancers, for example, excessive dose to the parotid glands and pharyngeal constrictors often resulted in severe xerostomia and dysphagia. Similarly, in abdominal radiotherapy, excessive bowel irradiation could lead to intolerable gastrointestinal toxicity.

These toxicities frequently forced clinicians to interrupt treatment or reduce delivered dose. Such interruptions are well known to compromise tumor control through accelerated tumor repopulation. Modern high-precision radiotherapy platforms fundamentally disrupt this loop. Through intensity modulation and volumetric arc therapy, radiation dose can be sculpted around complex anatomical structures with steep dose gradients. Image guidance using cone beam CT further ensures accurate daily patient positioning.

The net effect is a substantial improvement in therapeutic ratio. Tumors can receive ablative or near-ablative radiation doses while adjacent normal tissues remain within safe tolerance limits.

4.4. Dosimetric precision and organ-at-risk sparing

Although the present audit focuses primarily on clinical and epidemiologic data, the dosimetric implications of modern planning techniques are evident.

High-precision treatment planning allows radiation oncologists to carefully evaluate volumetric dose parameters such as:

- PTV V95 coverage
- Mean parotid dose
- Mandibular maximum dose
- Lung V20
- Mean heart dose
- Bowel and rectal dose constraints

Such parameters were either unavailable or extremely difficult to evaluate during the era of two-dimensional planning.

In breast radiotherapy, for example, modern techniques allow careful monitoring of mean heart dose and ipsilateral lung dose. In head-and-neck cancers, parotid sparing IMRT has been shown in randomized trials to significantly reduce xerostomia without compromising tumor control.

These improvements translate directly into better long-term quality of life for cancer survivors.

4.5. Expansion of stereotactic and ablative therapies

Another major consequence of high-precision radiotherapy platforms is the expansion of stereotactic treatment approaches. Stereotactic body radiotherapy (SBRT) enables delivery of extremely high biologically effective doses in a small number of fractions. Such treatments have demonstrated excellent local control rates in several disease sites including lung tumors, liver metastases, and spinal metastases.

In the present audit, stereotactic techniques were used in a subset of patients. Although the proportion remains relatively small, the availability of these technologies dramatically expands treatment options, particularly for medically inoperable patients.

For patients with oligometastatic disease, SBRT has emerged as an important treatment strategy capable of prolonging survival. Trials such as SABR-COMET have demonstrated significant improvements in overall survival when stereotactic radiotherapy is applied to selected metastatic lesions.

Thus, technological modernization not only improves traditional radiotherapy but also introduces entirely new therapeutic paradigms.

4.6. Clinical outcomes and disease control

One of the most encouraging findings of this audit is the improvement in disease control rate observed following the adoption of precision radiotherapy techniques. Disease control improved from 66% in the legacy cohort to nearly 80% in the precision cohort. While this improvement cannot be attributed solely to technological factors—since advances in systemic therapy and surgical techniques also play important roles—the improved dosimetric precision likely contributes significantly to better tumor control.

Importantly, this improvement occurred despite the high burden of comorbidities present within the patient population. More than half of patients had at least one systemic comorbidity, with diabetes and hypertension being the most common. Patients with such comorbid conditions often tolerate aggressive treatment poorly. Precision radiotherapy techniques that minimize collateral toxicity therefore play an important role in enabling completion of treatment without interruption.

4.7. Real-world implications for regional oncology centers

Perhaps the most important implication of this audit is that meaningful improvements in cancer care can be achieved through technological modernization even within regional centers. Much of the literature on advanced radiotherapy techniques originates from large academic institutions in high-income countries. However, the majority of the world's cancer patients are treated in smaller regional centers.

Demonstrating that precision radiotherapy technologies can produce measurable improvements in outcomes within such settings is therefore extremely important.

These findings support continued investment in modern radiotherapy infrastructure, training, and workflow optimization within developing healthcare systems.

5. Limitations

Several limitations of the present study should be acknowledged.

- First, this study represents a retrospective audit from a single institution. Although the dataset includes a large number of patients, the findings may not be generalizable to all oncology centers.
- Second, the follow-up duration for some patients remains limited, particularly for those treated in the most recent period. Longer follow-up will be required to evaluate long-term survival outcomes.
- Third, the study primarily evaluates disease control rates rather than overall survival or progression-free survival. Future analyses incorporating Kaplan–Meier survival curves and multivariate regression analysis would provide additional insight into treatment effectiveness.
- Despite these limitations, the large patient cohort and real-world clinical setting provide valuable insights into contemporary radiotherapy practice.

6. Conclusion

This comprehensive institutional audit demonstrates that technological modernization in radiation oncology produces measurable improvements in treatment precision, workflow efficiency, and clinical outcomes. The transition from legacy two-dimensional radiotherapy techniques to high-precision digital platforms enables radiation oncologists to deliver conformal dose distributions with steep dose gradients while respecting critical organ constraints. These capabilities fundamentally improve the therapeutic ratio of radiation therapy. Within the present cohort of 1,192 patients, this technological evolution was associated with improved disease control outcomes despite a high burden of advanced disease and systemic comorbidities.

Equally important, the adoption of modern radiotherapy platforms expands the therapeutic scope of radiation oncology. Techniques such as VMAT, IMRT, and stereotactic radiotherapy allow clinicians to treat complex tumors and oligometastatic disease with curative intent in situations where treatment options were previously limited.

For regional cancer centers serving large populations, these technologies represent not merely incremental improvements but transformative advances in oncologic care.

Continued investment in high-precision radiotherapy infrastructure, workforce training, and workflow optimization will therefore play a critical role in improving cancer outcomes in the coming decades.

References

- [1] Bortfeld T. IMRT: review and preview. *Phys Med Biol.* 2006;51:R363-R379.
- [2] Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. *Med Phys.* 2008;35:310-317.
- [3] Ling CC, Zhang P, Archambault Y, et al. Commissioning and clinical implementation of RapidArc radiotherapy. *Int J Radiat Oncol Biol Phys.* 2008;72:575-581.
- [4] Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives. *Nat Rev Clin Oncol.* 2012;9:688-699.
- [5] Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia and Central America: a population-based study. *Lancet Oncol.* 2010;11:165-173.
- [6] Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment. *Cancer.* 2005;104:1129-1137.
- [7] Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity-modulated versus conventional radiotherapy in head and neck cancer (PARSPORT). *Lancet Oncol.* 2011;12:127-136.
- [8] Timmerman R, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *J Clin Oncol.* 2010;28:4070-4076.
- [9] Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. *Med Phys.* 2010;37:4078-4101.
- [10] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for oligometastatic tumors (SABR-COMET): a randomized trial. *Lancet.* 2019;393:2051-2058.